Your browser version may not work well with NCBI's Web applications. More information here...
1: Transpl Int. 1997;10(6):462-5.Click here to read Links

Two grams daily of oral acyclovir reduces the incidence of cytomegalovirus disease in CMV-seropositive liver transplant recipients.

Gavaldà J, de Otero J, Murio E, Vargas V, Rosselló J, Calicó I, Margarit C, Pahissa A.

Division of Infectious Diseases, Hospital General Universitari Vall d'Hebron, Barcelona, Spain. jPgavalda@ar.vhebron.es

Our objective in this study was to determine the efficacy of 2 grams a day of oral acyclovir administered for 16 weeks after transplantation for the prevention of cytomegalovirus (CMV) infection and disease in CMV-seropositive liver transplant recipients. Seventy-three adult liver transplant recipients, seropositive for CMV, were randomized to receive either 2 grams a day of oral acyclovir for 16 weeks after transplantation or no prophylaxis. The incidence of CMV disease was significantly lower in the acyclovir group (5%) than in the control group (27%; P < 0.05). By log-rank analysis, the differences in the probability of presenting CMV disease over the first 16 weeks and over the 1st year were also significant (P < 0.05). We conclude that 2 grams a day of oral acyclovir provides effective prophylaxis against CMV disease in CMV-seropositive liver transplant recipients.

PMID: 9428121 [PubMed - indexed for MEDLINE]

Patient Drug Information

  • Acyclovir (Zovirax® )

    Acyclovir is used to decrease pain and speed the healing of sores or blisters in people who have varicella (chickenpox), herpes zoster (shingles; a rash that can occur in people who have had chickenpox in the past), and ...

  • Source: AHFS Consumer Medication Information